BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer

Jiahua Jiang, Anita Thyagarajan-Sahu, Jagadish Loganathan, Isaac Eliaz, Colin Terry, George Sandusky, Daniel Sliva

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.

Original languageEnglish
Pages (from-to)1139-1145
Number of pages7
JournalOncology Reports
Volume28
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Triple Negative Breast Neoplasms
Lung Neoplasms
Breast
Animal Models
Breast Neoplasms
Neoplasm Metastasis
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Scutellaria
Astragalus membranaceus
Body Weight
Reishi
CXC Chemokines
Curcuma
Control Groups
Chemokine Receptors
Agaricales
Liver
Quercetin
Biological Factors

Keywords

  • C-X-C chemokine receptor-4
  • Dietary supplement
  • Lung cancer metastasis
  • Triple negative breast cancer cells
  • Urokinase plasminogen activator

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. / Jiang, Jiahua; Thyagarajan-Sahu, Anita; Loganathan, Jagadish; Eliaz, Isaac; Terry, Colin; Sandusky, George; Sliva, Daniel.

In: Oncology Reports, Vol. 28, No. 4, 10.2012, p. 1139-1145.

Research output: Contribution to journalArticle

Jiang, Jiahua ; Thyagarajan-Sahu, Anita ; Loganathan, Jagadish ; Eliaz, Isaac ; Terry, Colin ; Sandusky, George ; Sliva, Daniel. / BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. In: Oncology Reports. 2012 ; Vol. 28, No. 4. pp. 1139-1145.
@article{3dc788bcef1d438f9a2cacbf8dc59cc3,
title = "BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer",
abstract = "We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67{\%} (control) to 20{\%} (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.",
keywords = "C-X-C chemokine receptor-4, Dietary supplement, Lung cancer metastasis, Triple negative breast cancer cells, Urokinase plasminogen activator",
author = "Jiahua Jiang and Anita Thyagarajan-Sahu and Jagadish Loganathan and Isaac Eliaz and Colin Terry and George Sandusky and Daniel Sliva",
year = "2012",
month = "10",
doi = "10.3892/or.2012.1936",
language = "English",
volume = "28",
pages = "1139--1145",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer

AU - Jiang, Jiahua

AU - Thyagarajan-Sahu, Anita

AU - Loganathan, Jagadish

AU - Eliaz, Isaac

AU - Terry, Colin

AU - Sandusky, George

AU - Sliva, Daniel

PY - 2012/10

Y1 - 2012/10

N2 - We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.

AB - We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.

KW - C-X-C chemokine receptor-4

KW - Dietary supplement

KW - Lung cancer metastasis

KW - Triple negative breast cancer cells

KW - Urokinase plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84866454139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866454139&partnerID=8YFLogxK

U2 - 10.3892/or.2012.1936

DO - 10.3892/or.2012.1936

M3 - Article

C2 - 22842551

AN - SCOPUS:84866454139

VL - 28

SP - 1139

EP - 1145

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -